Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection-Reference-Cited by-同舟云学术

Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection

Published:2022-04-14 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Waqas Muhammad,Mohib Khadija,Saleem Aniqa,LNU Mahak,Arjumand Sabeen,Khalil Hafiz Habib Ur Rehman,Nosheen Rukhshanda,Abbas Sharmeen,Maqsood Kanza M,Abbas Kiran

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference27 articles.

1. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection;Hickson M;Therap Adv Gastroenterol,2011

2. Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate;Lynch T;PLoS One,2013

3. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics;Hensgens MP;J Antimicrob Chemother,2012

4. Host and pathogen factors for Clostridium difficile infection and colonization;Loo VG;N Engl J Med,2011

5. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review;Abou Chakra CN;PLoS One,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fighting against Clostridioides difficile infection: Current medications;International Journal of Antimicrobial Agents;2024-07

2. Clinical Practice Guidelines of the Scientific Society for the Clinical Study of Human Microbiome, of the Russian Gastroenterological Association and the Russian Society for the Prevention of Noncommunicable Diseases on the Diagnosis and Treatment of <i>Clostridioides difficile</i> (<i>C. difficile</i>)-associated Disease in Adults;Russian Journal of Gastroenterology, Hepatology, Coloproctology;2023-08-22